8-K: Johnson & Johnson Reports Mixed Q3 Results, Updates Full-Year Guidance

Johnson & Johnson announced a 5.2% increase in reported sales for Q3 2024, alongside a decrease in earnings per share due to a one-time charge and acquired IPR&D.

Summary

• Johnson & Johnson reported a 5.2% increase in reported sales to $22.5 billion for the third quarter of 2024.
• Operational sales grew by 6.3%, while adjusted operational sales increased by 5.4%.
• Earnings per share (EPS) decreased by 34.3% to $1.11, impacted by a one-time special charge and acquired IPR&D.
• Adjusted EPS decreased by 9.0% to $2.42, also affected by acquired IPR&D.
• The company increased its full-year 2024 operational sales guidance.
• Full-year 2024 adjusted operational EPS guidance was updated to $9.91, reflecting improved performance offset by the acquisition of V-Wave.
• Free cash flow year-to-date is estimated at $14 billion.
• Innovative Medicine operational sales grew by 6.3%, driven by several key products.
• MedTech operational sales grew by 6.4%, with acquisitions positively impacting growth by 2.7%.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative due to the mixed results. While sales growth is positive, the significant decrease in EPS and the negative impact of the V-Wave acquisition on guidance temper the overall outlook.

Positives

• Reported sales increased by 5.2% to $22.5 billion in Q3 2024.
• Operational sales grew by 6.3% in Q3 2024.
• The company increased its full-year 2024 operational sales guidance.
• Significant pipeline progress was made with several regulatory approvals and submissions.
• Free cash flow year-to-date is estimated at $14 billion.
• Innovative Medicine and MedTech segments both showed strong operational sales growth.
• The company launched new products including VELYS Spine and Shockwave E8 IVL Catheter.

Negatives

• Q3 2024 earnings per share decreased by 34.3% to $1.11.
• Adjusted EPS decreased by 9.0% to $2.42 in Q3 2024.
• The acquisition of V-Wave negatively impacted the full-year adjusted operational EPS guidance by $0.24.
• Net earnings decreased by 37.5% to $2.694 billion.
• Some products like STELARA and SIMPONI/SIMPONI ARIA saw sales declines.

Risks

• The company faces risks related to economic factors, competition, and new product development.
• There are uncertainties in clinical success and obtaining regulatory approvals.
• The company is exposed to risks from product efficacy or safety concerns, potentially leading to recalls or regulatory action.
• Significant adverse litigation or government action, including product liability claims, could impact the company.
• Changes in applicable laws and regulations, including tax laws and global health care reforms, pose risks.
• The company is exposed to financial instability of international economies and legal systems and sovereign risk.
• The company's ability to realize the anticipated benefits from the separation of Kenvue Inc. is a risk.

Future Outlook

Johnson & Johnson updated its full-year 2024 guidance, increasing operational sales guidance and adjusting operational EPS guidance to $9.91, reflecting improved performance and the impact of the V-Wave acquisition.

Management Comments

• Joaquin Duato, Chairman and Chief Executive Officer, stated that Johnson & Johnson's strong results in the third quarter reflect the unique breadth of their business and commitment to delivering the next wave of healthcare innovation.
• He also mentioned the advancement of their pipeline with regulatory approvals for TREMFYA and RYBREVANT, and the submission of an IDE for their general surgery robotic system, OTTAVA.

Industry Context

This announcement reflects the ongoing trends in the healthcare industry, including the focus on innovative medicines, medical technology advancements, and the impact of acquisitions on financial performance. The regulatory approvals and product launches highlight the company's efforts to maintain a competitive edge in the market.

Comparison to Industry Standards

• Johnson & Johnson's 5.2% reported sales growth is comparable to other large pharmaceutical and medical device companies, such as Medtronic (MDT) and Abbott (ABT), which have also reported mid-single-digit growth in recent quarters.
• The 6.3% operational sales growth is a positive sign, indicating strong underlying business performance, similar to what might be seen in companies like Stryker (SYK) in the MedTech space.
• However, the 34.3% decrease in EPS is a significant concern, and is worse than what many of its peers have reported, indicating the impact of the one-time charge and acquired IPR&D.
• The adjusted EPS decrease of 9.0% is also a negative, and is worse than the results of companies like Pfizer (PFE) and Merck (MRK) who have reported flat or positive adjusted EPS growth.
• The updated full-year adjusted operational EPS guidance of $9.91, which includes a $0.24 negative impact from the V-Wave acquisition, is a mixed signal, as it shows improved performance offset by acquisition costs, which is a common theme in the industry.
• The free cash flow of $14 billion year-to-date is a strong result, and is comparable to other large healthcare companies, indicating good cash generation capabilities.

Management Changes

Legal Proceedings

• Johnson & Johnson announced that its subsidiary, Red River Talc LLC, has filed a voluntary prepackaged Chapter 11 case to resolve all current and future ovarian cancer talc claims.

Stakeholder Impact

• Shareholders may be concerned about the decrease in EPS and the negative impact of the V-Wave acquisition on guidance.
• Employees may be affected by the restructuring and changes in personnel.
• Customers will benefit from the new product launches and advancements in healthcare innovation.
• Suppliers may see changes in demand due to the company's restructuring and acquisitions.
• Creditors will be interested in the company's financial performance and cash flow.

Next Steps

• Johnson & Johnson will conduct a conference call with investors to discuss the earnings release.
• The company will continue to advance its pipeline and launch new products.
• The company will continue to monitor and manage the impact of the V-Wave acquisition.

Key Dates

Keywords

Johnson & Johnson, JNJ, earnings, sales, Q3 2024, EPS, operational sales, MedTech, Innovative Medicine, guidance, TREMFYA, RYBREVANT, V-Wave, DARZALEX, pipeline, regulatory approvals